IOIS 2021 Congress – Educational Industry Symposia
SANTEN
| FRIDAY 12:00 | Educational Industry-sponsored symposium - Santen | ||
| Welcome and introduction | BODAGHI B | ||
| From initial diagnosis to assessing disease progression in DED | ROLANDO M | ||
| How to implement a stepwise approach to the management of DED in clinical practice | MESSMER E | ||
| Changing the PERSPECTIVE on DED treatment: evidence from the real-world setting | GEERLING G | ||
| Q & A - All faculty | |||
| End of Session | |||
NOVARTIS
| FRIDAY 17:00 | Educational Industry-sponsored symposium - Novartis | ||
| TITLE: nAMD Management - Expert Insights at Each Step Along the Patient Journey | |||
| Moderator | BODAGHI B | ||
| Welcome | BODAGHI B | ||
| Introduction to nAMD - Unmet need in patients with nAMD and anti-vascular endothelial growth factor (anti-VEGF) efficacy and safety | PAVESIO C | ||
| Benefit/risk profile of brolucizumab | KHORAMNIA R | ||
| Key findings that support informed treatments decisions along the patient journey | KHANANI A | ||
| Case Study 1: Efficacy of brolucizumab in a patient with unresolved fluid despite previous anti-VEGF treatment | NGUYEN Q | ||
| Case Study 2: Adverse event management in a brolucizumab patient resulting in reversal of vision loss | NGUYEN Q | ||
| Conclusion | |||
Affibody
| SATURDAY 12:00 | Educational Industry-sponsored symposium - Affibody | ||
| Moderator > Panel Discussion | NGUYEN Q | ||
| Topic: IL-17 inhibition in the management of non-infectious uveitis | |||
| Introduction to the Affibody@technology | BEJKER David CEO, Affibody | ||
| The ABY-035 molecule | FREJD Fredrik CSO, Affibody | ||
| Unmet medical need in managing non-infectious uveitis: target therapy | MISEROCCHI E | ||
| How to LINNAEA study may address the unmet medical need | NGUYEN Q | ||
| Panel Discussion | NGUYEN Q, MISEROCCHI E, ADAN A, BBODAGHI B | ||
| End of Session | |||
Alimera Sciences
| SATURDAY 17:00 | Educational Industry-sponsored symposium - Alimera Sciences | ||
| Moderator / Chair | PAVESIO C | ||
| TOPIC: Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye - evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant – lessons learned in the last 2 years | |||
| Welcome & Introductions | PAVESIO C | ||
| The French Experience | BODAGHI B | ||
| The German Experience | KHORAMNIA R | ||
| The USA Experience | NGUYEN Q | ||
| Q & A | |||
| End of Session | |||